Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB05170_nanopub.RA8N94v1ISxknNT59N6GNFiOfZU_XyJAsu0Mokq0uvVJw#assertion>. }
Showing items 1 to 12 of
12
with 100 items per page.
- drugbank:DB05170 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05170 label "Benzimate [drugbank:DB05170]" assertion.
- drugbank:DB05170 seeAlso DB05170 assertion.
- drugbank:DB05170 description "Benzimate is the lead compound selected from a series of compounds known as benzimidazoles. The anti-cancer and anti-viral activity of the benzimidazoles was originally investigated by the Proctor & Gamble Company beginning in the 1990's. It is currently under investigation by AmpliMed and is in phase I of clinical trial." assertion.
- drugbank:DB05170 identifier "drugbank:DB05170" assertion.
- drugbank:DB05170 title "Benzimate" assertion.
- drugbank:DB05170 drugbank_vocabulary:x-cas cas: assertion.
- drugbank:DB05170 drugbank_vocabulary:drugbank-id "DB05170" assertion.
- drugbank:DB05170 bio2rdf_vocabulary:x-identifiers.org DB05170 assertion.
- drugbank:DB05170 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05170" assertion.
- drugbank:DB05170 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05170 bio2rdf_vocabulary:identifier "DB05170" assertion.